M&A, Integration & Capital Raises
Operator-Led M&A Advisory and Capital Raise Strategy
Biopharma transactions are among the most complex and high-stakes decisions a company will ever make. The difference between a deal that creates lasting value and one that destroys it is rarely the asset or the price. It is the quality of the strategic preparation, the rigor of the execution, and the experience of the team navigating it.
At Katogen, we bring 17 completed acquisitions and USD 4B+ raised to every M&A and capital raise engagement. We have been on both sides of the table — as acquirer, as acquired, and as the operator responsible for making the deal work after close. That experience is the foundation of everything we do.
What We Do
Deal Thesis Development Before a transaction begins, we help you answer the most important question: why does this deal make strategic sense, and what does success look like 18 months post-close? A clear, defensible deal thesis is the foundation of every value-creating acquisition.
Acquirer Mapping and Target Identification We help growth-stage companies map their likely acquirer landscape — understanding who will want to buy them, why, and at what strategic premium — so they can proactively position for the right conversation rather than react to inbound interest.
Transaction Preparation and Diligence Support We prepare companies for the diligence process — identifying and addressing the issues a sophisticated acquirer will find before they find them. Clean CMC, credible supply chain, defensible reimbursement strategy, strong organizational narrative. We build the story and fix the gaps.
Capital Raise Strategy We have raised USD 4B+ across multiple biopharma builds and turnarounds. We know what sophisticated institutional investors and strategic partners look for — and we help leadership teams build the financial narrative, investor materials, and capital strategy to attract the right capital at the right terms.
Integration Planning and Execution Most biopharma deals fail not in the negotiation but in the integration. We help acquiring companies build integration plans that begin during diligence — not after close — covering talent retention, organizational design, regulatory alignment, and commercial execution.
Who This Is For
CEOs and executive teams at growth-stage and mid-sized biopharma companies preparing for or navigating a transaction — whether as buyer, seller, or capital raiser. Also relevant for companies that have recently completed an acquisition and need experienced operator support to make the integration work.
Why Katogen
Seventeen acquisitions. USD 4B+ raised. CEO roles at Alvogen, Cybin, and multiple other biopharma companies. We do not advise on transactions from the outside — we have executed them from the inside.